Document is current
Any future updates will be listed below
-
Authors
Yang, Zhuolin
Wang, Xianggui
Wang, Xiaojing
Ding, Wenjiao
Zhang, Yiyu
Gu, Qingling
Wang, Wenqing
Miao, Yousi
Xie, Ping
Huang, Min
Jiang, Hua
Mo, Xiaolan
Li, Jiali
-
Funding
Funding for this research was provided by:
Guangdong Provincial Key Laboratory of Construction Foundation (2017B030314030)
Wu Jieping Medical Foundation (320.6750.2022-20-26)
Guangzhou Science and Technology Bureau program (SL2022B03J01382)
- License Information
-
More Information
Article History
Received: 5 July 2025
Accepted: 2 December 2025
First Online: 19 December 2025
Declarations
:
: This study was conducted according to the Declaration of Helsinki and approved by the Ethics Committee of Guangzhou Women and Children’s Medical Center (Title of the approved project: Study on individualized medication for acute graft-versus-host disease after hematopoietic stem cell transplantation in children; Name of the institutional approval committee or unit: Ethics Committee of Guangzhou Women and Children’s Medical Center; Approval number: Guangzhou Women and Children’s Medical Center, Issue No.63100 [2020], EC; Date of approval: November 27, 2020), and it was registered at Chinese Clinical Trial Registry (ChiCTR2000040561). All patients’ guardians signed informed consent.
: The authors declare no competing interests.
